Rivaroxaban is an oral factor Xa inhibitor that provides anticoagulation without the need for monitoring that was recently studied for use in non-valvular atrial fibrillation in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) [32,33]. This evidence concerns the gene F10 and Stroke.